Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
30.37 USD -0.26% Intraday chart for Royalty Pharma plc -0.20% +8.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023. CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases MT
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M MT
Novartis wants to swallow Morphosys - access to beacon of hope DP
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16 MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024 CI
Transcript : Royalty Pharma plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM
Royalty Pharma Insider Sold Shares Worth $13,222,862, According to a Recent SEC Filing MT
Royalty Pharma plc and Royalty Pharma Holdings Ltd Enters into Amendment No. 3 to the Amended and Restated Revolving Credit Agreement CI
PureTech Health Provides Updates on Programs, Reports Strong Financial Position MT
Morphosys raises more than 100 million euros with capital increase DP
The only way is up… Our Logo
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty... Our Logo
Transcript : Royalty Pharma plc Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 03:00 PM
MORPHOSYS IN FOCUS: The shaken belief in a blockbuster DP
MedinCell: collaboration between Teva and Royalty Pharma CF
Teva Pharmaceuticals International GmbH and Royalty Pharma plc Collaborate to Further Accelerate Olanzapine LAI Program CI
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating MT
Chart Royalty Pharma plc
More charts
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.37 USD
Average target price
45.4 USD
Spread / Average Target
+49.49%
Consensus
  1. Stock
  2. Equities
  3. Stock Royalty Pharma plc - Nasdaq
  4. News Royalty Pharma plc
  5. Blueprint Medicines Secures $1.25 Billion Strategic Financing Via Partnerships with Royalty Pharma